KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Beginning Cash BalanceCash from Discontinued OperationsCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TherapeuticsMD (TXMD) Gains from Investment Securities: 2011-2025

Historic Gains from Investment Securities for TherapeuticsMD (TXMD) over the last 13 years, with Sep 2025 value amounting to $51,000.

  • TherapeuticsMD's Gains from Investment Securities fell 17.74% to $51,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $51,000, marking a year-over-year decrease of 17.74%. This contributed to the annual value of $57,000 for FY2024, which is 65.03% down from last year.
  • As of Q3 2025, TherapeuticsMD's Gains from Investment Securities stood at $51,000, which was down 0.00% from $51,000 recorded in Q2 2025.
  • Over the past 5 years, TherapeuticsMD's Gains from Investment Securities peaked at $23.5 million during Q2 2021, and registered a low of -$721,000 during Q3 2023.
  • For the 3-year period, TherapeuticsMD's Gains from Investment Securities averaged around $132,915, with its median value being $51,000 (2025).
  • In the last 5 years, TherapeuticsMD's Gains from Investment Securities soared by 135,669.23% in 2021 and then plummeted by 465.99% in 2023.
  • Over the past 5 years, TherapeuticsMD's Gains from Investment Securities (Quarterly) stood at $353,000 in 2021, then slumped by 51.27% to $172,000 in 2022, then spiked by 1,243.60% to $2.3 million in 2023, then slumped by 97.53% to $57,000 in 2024, then declined by 17.74% to $51,000 in 2025.
  • Its Gains from Investment Securities stands at $51,000 for Q3 2025, versus $51,000 for Q2 2025 and $52,000 for Q1 2025.